An experience of vaccination against pneumococcal infection of adults at Krasnoyarsk krai

The aim of the study was to investigate efficacy of specific prevention of pneumococcal infection in high-risk group patients living at Krasnoyarsk krai. Methods. The study involved 12,080 patients with a high risk of pneumococcal infection including patients with chronic lung diseases, chronic heart failure (CHF) and diabetes mellitus. A special questionnaire was developed which included medical history for the previous 1 year and for 1 year after the vaccination. Results. CHF was diagnosed in 41.08% of patients, diabetes was diagnosed in 28.44%, chronic lung diseases were diagnosed in 30.07%; 2.4% of patients had pneumonia. PCV13 vaccine (Prevenar 13) was used in 9,986 patients (82.67%) including 5,070 patients (41.97%) vaccinated against flu and pneumococcus simultaneously. PPV23 (Pneumo-23) vaccine was used in 1,967 patients (16.28%) including 1,181 patients (9.83%) vaccinated against flu and pneumococcus simultaneously. Due to the broad-scale vaccination against pneumococcal infection, exacerbation rate reduced trice, number of hospitalisations related to exacerbations reduced by 11.5 times, morbidity of pneumonia reduced by 4.8 times, morbidity of acute respiratory infections and flu reduced by 6.6 times. Conclusion. The results confirmed high efficacy and safety of 13-valent conjugate pneumococcal vaccine and 23-valent polysaccharide pneumococcal vaccine. The vaccination allowed reducing morbidity of respiratory infection and decrease number of hospitalisations due to exacerbations of chronic diseases.

1. World Health Organization. Pneumococcal conjugated vaccine for childhood immunization – WHO position paper. Wkly Epidemiol. Rec. 2007; 7: 93–104.

2. Fedoseenko M.V. Perspectives of vaccination against pneumococcal infections: current view. Russkiy meditsinskiy zhurnal. 2009; 1: 36 (in Russian).

3. Uchaykin V.F., Shamsheva O.V. Pneumococcal Infections. A Handbook on Clinical Vaccinology. Moscow; 2006 (in Russian).

4. Raynert R.R., Tayshi B. New data on efficacy of 13-valent conjugate pneumococcal vaccine against invasive pneumococcal infections, pneumonias, and acute otitis media. Pediatricheskaya farmakologiya. 2012; 9 (3): 12–18 (in Russian).

5. Kolosov V.P., Kurganova O.P., Tezikov N.L., et al. Epidemiology of community-acquired pneumonia in Amur region: problems and their solutions. Byulleten' fiziologii i patologii dykhaniya. 2014; 53: 8–17 (in Russian).

6. Gurevich K.G., Fesyun A.V., Svistunov O.P., et al. Hidden issues of efficacy and safety of pneumococcal vaccination. Sistemnyy analiz i upravlenie v biomeditsinskikh sistemakh. 2013; 12 (1): 140–144 (in Russian).

7. Myint P.K., Kwok C.S., Majumdar S.R. et al. The International Community-Acquired Pneumonia (CAP) Collaboration Cohort (ICCC) study: rationale, design and description of study cohorts and patients. Br. Med. J. Open. 2012; 2 (3): e001030. DOI: 10.1136/bmjopen-2012-001030.

8. Belov B.S., Nasonov E.L. Vaccination in rheumatic diseases: actuality and perspectives. Revmatologiya. 2011; 25: 1511–1517 (in Russian).

9. Bewick T., Sheppard C., Greenwood S. et al. Serotype prevalence in adults hospitalised with pneumococcal non-invasive community-acquired pneumonia. Thorax. 2012; 67 (6): 540–545. DOI: 10.1136/thoraxjnl-2011-201092.

10. Singanayagam A., Singanayagam A., Elder D., Chalmers J.D. Is community-acquired pneumonia an independent risk factor for cardiovascular disease? Eur. Respir. J. 2011; 39 (1): 187–196. DOI: 10.1183/09031936.00049111.

11. Bottle A., Aylin P., Bell D. Effect of the readmission primary diagnosis and time interval in heart failure patients: analysis of English administrative data. Eur. J. Heart. Fail. 2014; 16 (8): 846–853. DOI: 10.1002/ejhf.129.

12. Kwon B.J., Kim D.B., Jang S.W. et al. Prognosis of heart failure patients with reduced and preserved ejection fraction and coexistent chronic obstructive pulmonary disease. Eur. J. Heart Fail. 2010; 12 (12): 1339–1344. DOI:10.1093/eurjhf/hfq157.

13. Arutyunov A.G., Dragunov D.O., Arutyunov G.P., et al. The first open study of acute exacerbation of chronic heart failure and comorbidity in Russian Federation. The ORAKUL-RF independent register. Kardiologiya. 2015; 55 (5): 12–21. DOI: 10.18565/cardio.2015.5.12-21 (in Russian).

14. American Diabetes Association. Standards of medical care in diabetes–2012. Diabet. Care. 2012; 35 (Suppl. 1): S11–S63. DOI: 10.2337/dc12-s011.

15. Kyaw M.H., Rose C.E. Jr, Fry A.M. et al. The influence of chronic illnesses on the incidence of invasive pneumococcal disease in adults. J. Infect. Dis. 2005; 192 (3): 377–386. DOI: 10.1086/431521.

16. Gayvoronskaya A.G., Namazova-Baranova L.S., Galitskaya M.G., et al. Efficacy and safety of vaccination against pneumococcal infection of children with different diseases. Pediatricheskaya farmakologiya. 2012; 2 (9): 10-14. DOI: 10.15690/pf.v9i2.238 (in Russian).

17. Reinert R.R., Tasy B. Effectiveness of the 13-valent pneumococcal conjugate vaccine: Emerging data from invasive pneumococcal diseases, pneumonia, acute otitis media and nasopharyngeal carriage. Pediatricheskaya farmakologiya. 2012; 9 (3): 8–11. DOI: 10.15690/pf.v9i3.315.

18. Kaplan S.L., Barson W., Lin P. et al. Early trends for invasive pneumococcal infections in children after the introduction of the 13-valent pneumococcal conjugate vaccine. Pediatr. Infect. Dis. J. 2013; 32 (3): 203–207. DOI: 10.1097/INF.0b013e318275614b.